• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

    10/6/25 7:30:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email

    Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Execution

    Arthur Tzianabos Resumes Chairman of the Board Role

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its Board of Directors has appointed Ian F. Smith as Chief Executive Officer (CEO). Mr. Smith has served as Interim CEO since March 2025 and as a member of Stoke's Board of Directors and advisor to the Company since 2023. He will continue to serve as a Director on the Company's Board of Directors. Arthur Tzianabos, Ph.D., has been a member of the Board of Directors since 2018. He will resume his role as Chairman of the Board after serving as Executive Chairman while the CEO search was conducted.

    A global Phase 3 study of the Company's lead investigational medicine, zorevunersen, is underway. Zorevunersen is a first-in-class potential disease-modifying medicine for Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments. In February 2025, Stoke entered a collaboration with Biogen Inc. to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.

    Dr. Tzianabos said, "After conducting a comprehensive search, it became clear that Ian is uniquely qualified to lead Stoke and deeply committed to our science, our mission, and our people. Under his leadership over the last six months, the team and the business have thrived, achieving multiple milestones, including the start of our pivotal Phase 3 EMPEROR study in Dravet syndrome, generation of new data to drive understanding of zorevunersen, and the expansion of our pipeline with the start of a second clinical program in Autosomal Dominant Optic Atrophy. This strong execution has translated into meaningful value creation for our shareholders. Ian's deep experience in rare disease drug development and commercialization, regulatory know-how, exceptional track record of building and leading teams, and comprehensive, multi-faceted understanding of our business are unmatched and will be invaluable as we continue to build Stoke into a world-class biotechnology company."

    Mr. Smith said, "As a Board member and advisor, I had established an appreciation for Stoke, and I have enjoyed my time working even more closely with the team as Interim CEO since March. I look forward to transitioning to the CEO and to continuing with the opportunity to build a company that has the potential to deliver first-in-class medicines to patients with severe genetic diseases – a mission both unique and deeply familiar to me. Over the last six months, we have strengthened our business and positioned Stoke for rapid advancement and growth. I look forward to continuing to work with this outstanding team to realize the full potential of our science and medicines."

    Mr. Smith has spent most of his career delivering life-changing medicines for patients with rare diseases. He previously served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals. Over the course of nearly two decades, he was instrumental in steering Vertex through key strategic pivots, transforming it from a research stage company into a global biopharmaceutical leader in rare disease innovation. Since 2019, Mr. Smith has held numerous board and advisory roles at several leading biotechnology companies.

    Ian F. Smith Biography

    Ian F. Smith is a biotechnology leader with more than 30 years of finance and operations experience and extensive relationships in the industry. Mr. Smith previously served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals from 2001 to 2019. Prior to his tenure at Vertex, he was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP. Mr. Smith currently serves as a senior advisor to Bain Capital Life Sciences, a position he has held since January 2021, and provides other advisory and consulting services to life science companies. He currently serves as Executive Chairman of the Board at Solid Biosciences and Chairman of the Board at Rivus Pharmaceuticals. He also sits on the Board of Directors for Foghorn Therapeutics, Alkeus Pharmaceuticals, Areteia Therapeutics, and Odyssey Therapeutics. Ian holds a B.A. with honors in accounting and finance from Manchester Metropolitan University (UK).

    Arthur Tzianabos, Ph.D. Biography

    Dr. Arthur Tzianabos was appointed to Stoke's Board of Directors in 2018 and was appointed Chair in 2024. He is currently CEO of Lifordi Immunotherapeutics and a venture partner at 5AM Ventures. He was previously CEO and later Chair of the Board of Directors at Homology Medicines, where he led the company from inception through a successful public offering. While at Homology, Dr. Tzianabos led efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. Dr. Tzianabos currently serves on the Board of Directors of Q32 Bio following its merger with Homology earlier this year. He was formerly Chair of the Board of Directors of Akouos, a publicly traded gene therapy company acquired by Lilly in 2022. Prior to this, he spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire's product pipeline through investments and acquisitions.

    Earlier in his career, Dr. Tzianabos was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters and patents. He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.

    About Stoke Therapeutics

    Stoke Therapeutics (NASDAQ:STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the design, timing and results of the Phase 3 study; the timing and expected progress of regulatory filings and regulatory decisions; the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; and the expectations regarding the business operations. Statements including words such as "anticipate," "expect," "plan," "will," or "may" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company's ability to protect its intellectual property; the Company's ability to fund development activities and achieve development goals through mid-2028; and the other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251006657082/en/

    Stoke Media & Investor Contacts:

    Dawn Kalmar

    Chief Communications Officer

    [email protected]

    781-303-8302

    Doug Snow

    Director, Communications & Investor Relations

    [email protected]

    508-642-6485

    Get the next $STOK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    7/18/2025$30.00Buy
    Jefferies
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    More analyst ratings

    $STOK
    SEC Filings

    View All

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    10/6/25 7:30:15 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Stoke Therapeutics Inc.

    144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

    10/3/25 4:35:12 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Stoke Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K/A - Stoke Therapeutics, Inc. (0001623526) (Filer)

    9/18/25 4:07:59 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaye Edward M. Md sold $1,065,206 worth of shares (42,461 units at $25.09), decreasing direct ownership by 46% to 49,124 units (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    10/7/25 4:26:59 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GENERAL COUNSEL & CORP SEC Allan Jonathan exercised 10,000 shares at a strike of $9.15 and sold $250,650 worth of shares (10,000 units at $25.07) (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    10/7/25 4:26:05 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Ticho Barry sold $126,316 worth of shares (5,343 units at $23.64), decreasing direct ownership by 29% to 13,126 units (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    10/3/25 4:25:38 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

    Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Execution Arthur Tzianabos Resumes Chairman of the Board Role Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its Board of Directors has appointed Ian F. Smith as Chief Executive Officer (CEO). Mr. Smith has served as Interim CEO since March 2025 and as a member of Stoke's Board of Directors and advisor to the Company since 2023. He will continue to serve as a Director on the Company's Board of Directors. Arthur Tzianabos, Ph.D., has

    10/6/25 7:30:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2025, it granted stock options to purchase an aggregate of 135,300 shares of common stock to five new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $23.40 per share, which is equal to the closing price o

    9/16/25 4:30:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

    – Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines – – Zorevunersen generally well tolerated across all studies – – Data support pivotal Phase 3 EMPEROR study now underway – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB), today announced

    9/2/25 7:00:00 AM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Stoke Therapeutics with a new price target

    Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $30.00

    7/18/25 8:16:37 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

    12/20/24 7:51:37 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

    Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

    10/14/24 7:42:47 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STOK
    Financials

    Live finance-specific insights

    View All

    Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well tolerated – – Phase 1 study of STK-002 initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder – – As of June 30, 2025, the Company had $355.0 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to mid-2028 and into launch readiness – – Webcast and conference call for analysts and investors a

    8/12/25 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the cal

    8/7/25 7:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

    Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

    2/18/25 6:00:00 AM ET
    $BIIB
    $PRAX
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Retail: Computer Software & Peripheral Equipment

    $STOK
    Leadership Updates

    Live Leadership Updates

    View All

    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

    – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

    9/4/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

    – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

    4/17/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Ian Smith to its Board of Directors

    – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

    9/20/23 4:30:00 PM ET
    $FHTX
    $SLDB
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care